Table 1 Patients’ characteristics.
From: Prognostic significance of bone marrow and spleen 18F-FDG uptake in patients with colorectal cancer
N (%) | |
|---|---|
Sex | |
Female | 164 (39.9) |
Male | 247 (60.1) |
Age (years) | |
< 70 | 262 (63.7) |
≥ 70 | 149 (36.3) |
ASA | |
1 | 198 (48.2) |
2 | 159 (38.7) |
3 and 4 | 49 (11.9) |
No data | 5 (1.2) |
BMI (kg/m2) | |
< 25 | 305 (74.2) |
≥ 25 | 106 (25.8) |
Preop-CEA (ng/mL) | |
< 5 | 273 (66.4) |
≥ 5 | 138 (33.6) |
Tumor location | |
Rt. colon | 122 (29.4) |
Lt. colon | 178 (43.3) |
Rectum | 112 (27.3) |
Tumor size (cm) | |
< 5 | 218 (53) |
≥ 5 | 193 (47) |
Histologic grade | |
G1 | 44 (10.7) |
G2 | 324 (78.8) |
G3 | 20 (4.9) |
Etc | 23 (5.6) |
LVI | |
Absent | 292 (71) |
Present | 108 (26.3) |
No data | 11 (2.7) |
Number of retrieved LNs | |
< 12 | 63 (15.3) |
≥ 12 | 348 (84.7) |
Stage | |
I and II | 192 (46.7) |
III | 169 (41.1) |
IV | 50 (12.2) |
MSI | |
MSS/MSI-low | 249 (60.6) |
MSI-high | 29 (7.1) |
No data | 133 (32.4) |
KRAS | |
Wild | 123 (29.9) |
Mutant | 59 (14.4) |
No data | 229 (55.7) |
Chemotherapy | |
No | 154 (37.5) |
Yes | 257 (62.5) |
NLR | |
< 3 | 264 (64.2) |
≥ 3 | 147 (35.8) |
TLR | |
Median (IQR) | 4.65 (3.449–6.475) |
BLR | |
Median (IQR) | 0.83 (0.730–0.955) |
SLR | |
Median (IQR) | 0.82 (0.740–0.910) |
